Financial Results for the Fiscal Year 2015, Ended December 31, 2015

I Su	immary	Information	P.1			
	1	Financial Results	P.1			
	2	Financial Conditions	P.1			
<u>I</u> Fir	nancial	Results for the FY2015	P.2			
	1	Statement of Income	P.2			
	2	Sales of Products	P.4			
	3	Balance Sheet	P.5			
	4	Statement of Cash Flows	P.6			
	5	Capital Expenditures	P.7			
	6	Depreciation/Amortization	P.7			
	$\overline{\mathcal{O}}$	Research and Development	P.7			
<u>II</u> Fir	nancial	Forecasts for the FY2016	P.8			
	1	Statement of Income	P.8			
	2	Sales of Products	P.10			
	3	Capital Expenditures	P.11			
	4	Depreciation/Amortization	P.11			
	5	Dividends	P.11			
IV Ta	IV Targets of "The medium-term management plan 2018" P.11					
[Important notes on forward-looking statements] P.12						
<u>ж</u> т.						

X This material is prepared based on Japan GAAP.

 $\,\,\%\,$ Amounts are rounded down to the nearest million yen.

February 3, 2016




I Summary Information


① Financial Results


(Millions of Yen)	2014 Jan - Dec <i>A</i>	FY2015 <i>B</i>	Change _{B-A}	Change (%) (B-A)/A	FY2016 forecast C	Change _{C-B}	Change (%) (<i>C-B)/B</i>
Net sales	58,089	62,378	4,288	7.4	61,000	∆1,378	△2.2
Operating income	5,033	4,919	△114	∆2.3	3,300	∆1,619	∆32.9
Ordinary income	5,168	5,135	∆33	∆0.6	3,400	∆1,735	∆33.8
Net income	3,394	3,527	133	3.9	2,300	∆1,227	∆34.8

※ Torii has changed the closing date of the accounting period from March 31 to December 31 since FY2014. FY2014 covered nine months from April to December 2014. Therefore figures from Jan to Dec 2014, the same term of the last year, is presented with Financial Results for FY2015. The calculation method of figures from Jan to Dec 2014 is explained on page 2.


(Reference)								
R&D expenses		4,878	5,237	358	7.3	4,700	∆537	△10.3
Earnings per share (EPS)	(¥)	119.94	124.65	4.71		81.27	∆43.38	
Return on equity (ROE)	(%)	4.3	4.3	0.0		_		
Ratio of ordinary income to total assets	(%)	5.6	5.4	∆0.2				
Ratio of operating income to net sales	(%)	8.7	7.9	∆0.8				
Return on assets (ROA)	(%)	3.7	3.7	0.0		_		







Net income(0.1 billion yen)



② Financial Conditions

(Millions of Yen)		December 31, 2014 <i>A</i>	December 31, 2015 <i>B</i>	Change _{B-A}	Change (%) (<i>B-A)/A</i>
Total assets		92,550	98,868	6,318	6.8
Total equity		80,225	82,826	2,601	3.2
Equity ratio	(%)	86.7	83.8	∆2.9	
Book value per share (BPS)	(¥)	2,834.82	2,926.81	91.99	

I Financial Results for the FY2015

※ Torii has changed the closing date of the accounting period from March 31 to December 31 since FY2014. Figures from Jan to Dec 2014, the same term of the last year, is presented with Financial Results for FY2015. The calculation method of figures from Jan to Dec 2014 is explained at below.

① Statement of Income

(Millions of Yen)	2014 Jan - Dec	FY2015 <i>B</i>	Change _{B-A}	Change (%) _{(B-A)/A}
Net sales X2	58,089	62,378	4,288	7.4
Sales of products <u>X1</u>	57,827	61,861	4,033	7.0
Renal disease and hemodialysis	24,437	27,627	3,189	13.1
Skin disease and allergens	11,687	11,875	187	1.6
HIV	15,527	16,330	802	5.2
Other	6,174	6,028	△145	△2.4
Other sales	262	517	254	97.1
Cost of sales X2	27,396	30,814	3,417	12.5
Cost of products sold	27,338	30,759	3,421	12.5
Other cost	57	54	riangle3	△5.9
Gross profit	30,693	31,564	871	2.8
Selling, general and administrative expenses	25,659	26,645	985	3.8
R&D expenses	4,878	5,237	358	7.3
Others	20,780	21,408	627	3.0
Operating income	5,033	4,919	△114	△2.3
Non-operating income	145	218	73	_
Non-operating expenses	10	2	△7	_
Ordinary income	5,168	5,135	∆33	riangle0.6
Extraordinary income	15	320	304	_
Extraordinary loss	364	196	△167	_
Income before income taxes	4,819	5,258	438	9.1
Income taxes	1,425	1,730	305	_
Net income	3,394	3,527	133	3.9

※1 For details, please refer to page 4.

X2 Commission income, which was included in other among the sales of products, is included in other sales as during this fiscal period ended December 31,2015. Also rent income of real estate is included in other sales. Accordingly, cost of real estate rent is included in other cost.

(Reference) Ratio to net sales

(%)	2014 Jan - Dec	FY2015	Change
	A	В	B-A
Cost of sales	47.2	49.4	2.2
SG&A	44.1	42.7	△1.4
R&D expenses	8.4	8.4	0.0
Operating income	8.7	7.9	∆0.8
Ordinary income	8.9	8.2	△0.7
Net income	5.8	5.7	△0.1


<u>〈Figures of Jan - Dec 2014 calculation method〉</u> Jan - Mar 2014 (FY2013 (12 months) – FY2013 First nine months (9 months)) + Apr - Dec 2014 (FY2014 (9 months))

[Factors in increase/decrease compared with the same term of the last year (Jan to Dec 2014)]



Net Sales (¥62,378 million : Increase ¥4,288 million year-on-year)

Operating income (¥4,919 million : Decrease ¥114 million year-on-year)



	se/ ueci ease
Cost of sales	: Increase in net sales, loss on abandonment of a part of inventory of CEDARTOREN
	over expiring date for use and changes in sales mix among the products
R&D expenses	: Increase in clinical study expenses (TO-203 rhinitis in children)
Others	: Increase in labor costs

Ordinary income (¥5,135 million : Decrease ¥33 million year-on-year) Special remarks: None

Net income (¥3,527 million : Increase ¥133 million year-on-year)

Jan-Dec 2014	Loss on retirement of noncurrent assets	¥ 364 million
FY2015	Gain on sales of land	¥ 320 million
	Impairment loss	¥ 142 million

Sales of Products

(Millions of Yen)	2014 Jan - Dec A	FY2015 <i>B</i>	Change _{B-A}	Change (%) (<i>B-A)/A</i>
Sales of Products	57,827	61,861	4,033	7.0
REMITCH	14,970	15,636	665	4.4
Oral anti-pruritus agent [Renal disease and hemodialysis]				
Truvada	12,717	12,938	221	1.7
Antiviral agent for HIV [HIV]				
ANTEBATE <mark>※1</mark>	6,747	6,881	133	2.0
Topical corticosteroid [Skin disease and allergens]				
Riona X2	1,811	5,034	3,222	177.9
Agent for hyperphosphatemia [Renal disease and hemodialysis]				
Stribild	2,466	3,133	667	27.1
Antiviral agent for HIV [HIV]				
FUTHAN X1	3,499	3,062	∆437	△12.5
Protease inhibitor [Renal disease and hemodialysis]				
KAYEXALATE ×1	2,253	2,288	35	1.6
Agent for hyperkalemia [Renal disease and hemodialysis]				
BIO-THREE	2,123	2,272	149	7.0
Viable bacterial preparations [Other]				
URINORM X1	1,901	1,604	△297	△15.6
Uricosuric agent [Renal disease and hemodialysis]				
LOCOID ×1	1,337	1,417	79	6.0
Topical corticosteroid [Skin disease and allergens]				
ZEFNART	1,450	1,407	∆43	∆3.0
Topical antifungal agent [Skin disease and allergens]				
Dovonex	1,670	1,265	∆405	∆24.3
Topical agent for psoriasis vulgaris [Skin disease and allergens]				
Magsent	1,192	1,143	∆48	∆4.1
Tocolysis in threatened premature labor Eclampsia-suppressing and treatment [Other]				
Others X3	3,685	3,775	90	2.4

%1 In-house products

****2** Launched on May 12, 2014

※3 Among them, the sales of CEDARTOLEN, launched on October 8, 2014, amounts to ¥511 million in FY2015 (¥80 million in Jan-Dec 2014).

(References) Sales and ratio of in-house products

(Millions of Yen)	2014 Jan - Dec A	FY2015 <i>B</i>	Change _{B-A}	Change (%) (B-A)/A
Sales of in-house products	17,650	17,567	∆83	△0.5
Ratio of in-house (%) product sales	30.5	28.4	△2.1	_

③ Balance Sheet

(Millions of Yen)	December 31, 2014	December 31, 2015	Change	Change (%)	Component ratio (%)
	<u>A</u>	B	B-A	(B-A)/A	(Dec 31, 2015)
Current assets	72,121	77,155	5,033	7.0	78.0
Cash and deposits	6,316	14,361	8,045		
Deposits in the cash management system	14,978	4,348	△10,629		
Notes and accounts receivable-trade	25,901	27,904	2,003		
Short-term investment securities	13,209	18,708	5,499		
Inventories	10,136	9,836	∆ 299		
Others	1,579	1,994	414		
Noncurrent assets	20,428	21,713	1,285	6.3	22.0
Property, plant and equipment	5,806	6,182	376		
Intangible assets	818	955	136		
Investments and other assets	13,803	14,575	772		
Investment securities	7,070	6,800	△270		
Long-term prepaid expenses	5,230	6,530	1,300		
Others	1,502	1,244	△257		
Total assets	92,550	98,868	6,318	6.8	100.0
Current liabilities	11,391	14,472	3,081	27.0	14.6
Accounts payable-trade	6,095	6,853	758		
Accounts payable-other	1,795	3,287	1,492		
Income taxes payable	273	1,915	1,642		
Accrued employees' bonuses	694	660	∆33		
Others	2,534	1,755	△778		
Long-term liabilities	933	1,569	636	68.2	1.6
Total liabilities	12,324	16,042	3,717	30.2	16.2
Shareholders' equity	79,847	82,127	2,280	2.9	83.1
Unrealized gain on available-for-sale securities	377	698	321	85.0	0.7
Total equity	80,225	82,826	2,601	3.2	83.8
Total liabilities and equity	92,550	98,868	6,318	6.8	100.0

Major factors in increase/decrease		
(Current assets)		
Short-term	:	Increase by acquisition of money trust and commercial paper
investment securities		
(Noncurrent assets)		
Long-term prepaid expenses	:	Increase by milestone payment in development and
		decrease by amortization of marketing rights
(Current liabilities)		
Accounts payable-trade	:	Increase by increase in purchasing products
(Equity)		
Shareholders' equity	:	Increase in net income and decrease by payment of dividends

④ Statement of Cash Flows

(Millions of Yen)	2014	FY2015	Change
	Jan - Dec	B	B-A
Income before income taxes	4,819	5,258	438
Depreciation and amortization	1,218	1,457	239
Impairment loss	-	142	142
Increase in trade notes	△2,510	∆2,003	507
and accounts receivable-trade		△2,005	
Decrease (Increase) in inventories	∆2,666	299	2,966
Increase in trade notes	664	758	93
and accounts payable-trade			
Increase (Decrease) in accounts payable-other	△676	1,453	2,130
Increase (Decrease) in	376	△1,300	∆1,676
long-term prepaid expenses	A 1 17C	A 412	760
Income taxes paid Other-net	∆1,176 529	△413 △714	763
Net cash provided by	529	△/14	∆1,243
	577	4,940	4,363
operating activities Purchases of property,			
plant and equipment	∆664	∆1,095	∆431
Proceeds from sales of property,			
plant and equipment	0	342	342
Purchases of intangible assets	∆403	∆389	14
Other-net	4,504	2,100	△2,404
Net cash provided by			
investing activities	3,437	957	∆2,479
Net cash used in		. 4 500	÷ 100
financing activities	∆1,472	△1,582	△109
Net Increase in	2 5 4 2	4.216	1 774
cash and cash equivalents	2,542	4,316	1,774
Cash and cash equivalents,	20.252	21.004	2 5 4 2
beginning of period	29,352	31,894	2,542
Cash and cash equivalents,	21.004	26.210	1 210
end of period	31,894	36,210	4,316

(*) Cash and cash equivalents consist of cash on hand and in banks without time deposits with maturities more than three months, deposits in the cash management system and marketable securities of which the period from the date of acquisition to the date of redemption is not more than three months.

<u>Major factors in increase/decrease</u> (Operating activities) Decrease (Increase) in inventories	: Jan-Dec 2014	Increase in inventories of products
Increase (Decrease) in long-term prepaid expenses	: FY2015	Increase by milestone payment in development and decrease by amortization of marketing rights
(Investing activities) Other-net	: Jan-Dec 2014	Redemption of securities

(5) Capital Expenditures

(Millions of Yen)	2014 Jan - Dec	FY2015	Change	Change (%) (B-A)/A
Capital expenditures	1,726	<u>в</u> 2,207	<i>B-A</i> 481	(<i>B-A)/A</i> 27.9
PP&E	1,286	1,802	516	40.1
Intangible assets	440	405	∆34	∆7.9

Descriptions of capital expenditures						
PP&E	: Investment in manufacturing facilities related to allergen products and					
	manufacturing facilities aiming to improve productivity					
Intangible assets	: Investment in software aiming to streamline operations					

6 Depreciation/Amortization

(Millions of Yen)	2014 Jan - Dec	FY2015	Change	Change (%)	
Depreciation		<u>8</u> 1,457	<u>B-A</u> 239	(<i>B-A)/A</i> 19.7	
Amortization of long-term prepaid expenses	918	824	∆94	△10.2	

O Research and Development

Development		Formulation/		Devel	lopment stage (domestic)			
code	Indication	Route of administration	Phase I	Phase II	Phase III	Application	Approval	Remarks
Skin disease and al	lergens							
TO-203 「MITICURE® House Dust Mite	House dust mite induced allergic asthma (Allergen Immunotherapy)	Sublingual tablet		Pha	Phase II / III r			 Licensing agreement signed with ALK for providing exclusive development and sales rights in Japan In-house
Sublingual Tablets	House dust mite induced allergic rhinitis in children (Allergen Immunotherapy)	Sublingual tablet		Phase III				 Licensing agreement signed with ALK for providing exclusive development and sales rights in Japan In-house
ТО-206	Japanese cedar pollinosis (Allergen Immunotherapy)	Sublingual tablet				Application		•In-house •NDA filing by Torii on December 25, 2015

Updates since the previous announcement on October 30, 2015 •TO-203(MITICURE® House Dust Mite Sublingual Tablets) for the indication of allergic rhinitis launched on December 3, 2015.

(previous announcement : Development stage[Approval])

•TO-206 NDA filing by Torii

·JTE-350(Allergen Scratch Extract Positive control (Torii) Histamine dihydrochloride) launched on January 18, 2016.

(previous announcement : Development stage Approval)

Ⅲ Financial Forecasts for the FY2016

① Statement of Income

(Millions of Yen)	FY2015 A	FY2016 forecast <i>B</i>	Change _{B-A}	Change (%) (<i>B-A)/A</i>
Net sales 💥	62,378	61,000	riangle1,378	△2.2
Sales of products	61,861	59,770	∆2,091	∆3.4
Renal disease and hemodialysis	27,627	25,710	△1,917	△6.9
Skin disease	10,970	9,080	∆1,890	△17.2
Allergens	905	1,870	964	106.5
HIV infection	16,330	17,320	989	6.1
Other	6,028	5,790	△238	∆4.0
Other sales	517	1,230	712	137.9
Cost of sales	30,814	30,500	∆314	riangle 1.0
Gross profit	31,564	30,500	∆1,064	∆3.4
SG&A	26,645	27,200	554	2.1
R&D expenses	5,237	4,700	△537	△10.3
Others	21,408	22,500	1,091	5.1
Operating income	4,919	3,300	△1,619	∆32.9
Ordinary income	5,135	3,400	△1,735	∆33.8
Net income	3,527	2,300	△1,227	∆34.8


※ Items of net sales including product categories are reorganized along with "The medium-term management plan 2018" (from FY2016 to FY2018), and the sales figures are expressed accordingly.

(%)	FY2015	FY2016 forecast	Change
	A	В	B-A
Cost of sales	49.4	50.0	0.6
SG&A	42.7	44.6	1.9
R&D expenses	8.4	7.7	△0.7
Operating income	7.9	5.4	∆2.5
Ordinary income	8.2	5.6	∆2.6
Net income	5.7	3.8	△1.9


(Reference) Ratio to net sales

[Factors in increase/decrease compared with the FY2015]

Net sales (¥61,000 million : Decrease ¥1,378 million year-on-year)



Operating income (¥3,300 million : Decrease ¥1,619 million year-on-year)



Major factors in incr	ease/decrease	
Cost of sales	: Decrease in net sales and increase in cost percentage due to Drug Price revisions	
R&D expenses	: Decrease in clinical study expenses (TO-206)	
Others	: Increase in amortization of marketing rights and sales promotion expenses	

Ordinary income (¥3,400 million : Decrease ¥1,735 million year-on-year)

Special remarks: None

Net income (¥2,300 million : Decrease ¥1,227 million year-on-year)

Special remarks: None

② Sales of Products

Millions of Yen)	FY2015 <i>A</i>	FY2016 forecast B	Change _{B-A}	Change (%) (<i>B-A)/A</i>	
Sales of Products	61,861	59,770	∆2,091	∆3.4	
REMITCH	15,636	13,150	∆2,486	△15.9	
Oral anti-pruritus agent [Renal disease and hemodialysis]					
Truvada	12,938	12,550	riangle388	∆3.0	
Antiviral agent for HIV [HIV infection]					
Riona	5,034	6,720	1,685	33.5	
Agent for hyperphosphatemia [Renal disease and hemodialysis]					
ANTEBATE 💥	6,881	5,960	∆921	∆13.4	
Topical corticosteroid [Skin disease]					
Stribild	3,133	3,550	416	13.3	
Antiviral agent for HIV [HIV infection]					
FUTHAN 💥	3,062	2,450	riangle 612	∆20.0	
Protease inhibitor [Renal disease and hemodialysis]					
BIO-THREE	2,272	2,320	47	2.1	
Viable bacterial preparations [Other]					
KAYEXALATE 💥	2,288	2,110	riangle 178	∆7.8	
Agent for hyperkalemia [Renal disease and hemodialysis]					
LOCOID 💥	1,417	1,330	riangle 87	riangle 6.1	
Topical corticosteroid [Skin disease]					
URINORM 💥	1,604	1,280	∆324	∆20.2	
Uricosuric agent [Renal disease and hemodialysis]					
Magsent	1,143	1,170	26	2.3	
Tocolysis in threatened premature labor Eclampsia-suppressing and treatment [Other]					
CEDARTOLEN X	511	1,040	528	103.2	
Japanese cedar pollinosis (Allergen Immunotherap [Allergens]	y)				
ZEFNART	1,407	1,020	∆387	∆27.5	
Topical antifungal agent [Skin disease]					
Others	4,528	5,120	591	13.1	

※ In-house products

(References) Sales and ratio of in-house products

(Millions of Yen)		FY2015	FY2016 forecast	Change	Change (%)
		A	В	B-A	(<i>B-A</i>)/A
Sales of in-house produc	ts	17,567	16,370	riangle1,197	△6.8
Ratio of in-house product sales	(%)	28.4	27.4	△1.0	_

③ Capital Expenditures

(Millions of Yen)	FY2015	FY2016 forecast	Change	Change (%)
	А	В	B-A	(B-A)/A
Capital expenditures	2,207	1,160	∆1,047	∆47.5
PP&E	1,802	756	∆1,046	riangle58.1
Intangible assets	405	404	riangle 1	riangle0.3

Descriptions of capita	l expenditures
PP&E	: Investment mainly in manufacturing facilities aiming to improve productivity
Intangible assets	: Investment in software aiming to streamline operations

④ Depreciation/Amortization

(Millions of Yen)	FY2015	FY2016 forecast	Change	Change (%)
	A	<u> </u>	B-A	(B-A)/A
Depreciation	1,457	1,438	△19	riangle1.4
Amortization of long-term	824	1,089	264	32.1
prepaid expenses	02.1	1,005	201	0211

⑤ Dividends

		FY2015	FY2016 forecast	Change	Change (%)
		A	В	B-A	(B-A)/A
Dividends per share	(¥)	48	48	0	0.0
Dividends payout ratio	(%)	38.5	59.1	20.6	_

IV Targets of "The medium-term management plan 2018"

(0.1 billions of yen)	FY2015	FY2016	FY2018	
	F12015	forecast	target <mark>%2</mark>	
Net sales	623	610	620	
Operating income prior to deduction of R&D expenses ×1	101	80	80	

*1 R&D expenses is difficult to foresee at the present moment as investments may fluctuate in medium-to long term growth. Therefore, Torii sets operating income prior to deduction of R&D expenses as a target.
*2 Targets are set based on certain assumptions such as Drug price revisions including Repricing for market expansion and impact of measures to increase the use of generic drugs. Torii will revise the targets on a timely basis if assumptions are drastically changed.

[Important notes on forward-looking statements]

The forecasts presented in this material are forward-looking statements. Reflecting assumptions based on information available on the date of publication, these statements are subject to inherent risks and uncertainties. Accordingly, unforeseen factors may cause actual results to differ materially from the projections contained herein.

Torii will not necessarily revise this material regardless of any new information, future events or other results. At the present moment, the following matters may be pointed out as risks or uncertain factors that could affect the Company's future results (but such risks or uncertain factors are not limited to these):

 \Diamond Changes in Pharmaceutical and Medical Device Law, Other Acts or Regulations

- $\diamondsuit \mathsf{Delay}$ or Discontinuance of Research and Development
- $\bigcirc \mathsf{Drug}$ Price Listing and Revisions

◇Adverse Drug Reactions

 \Diamond Stoppage of Product Supply and Product Recall

◇Litigation Risk